PDB ID for probe-target interaction (3D structure):
5EPJ
Structure-activity relationship:
Detailed SAR data are available in a J. Med. Chem. publication that should be available shortly. SAR data were determined using an AlphaScreen assay, which is a bead-based competition assay that utilizes His-tagged proteins and biotinylated-peptide bait ligands. The SAR study primarily explored ligand length, unnatural methyl-lysine mimetics, and N-terminal modifications, as well as modifications to the phenylalanine side chain, alanine side chain, and C terminus. We found that certain tertiary amine mimetics of trimethyl-lysine are able to maintain similar affinities for chromodomains as Kme3 and Kme3 derivatives are not active in cells. A thorough examination of the N terminus of our inhibitors has also begun to establish the requirements for optimizing potency and selectivity for the Pc, HP1 and CDY families of chromodomains. CBX4/7 show a strong preference for alkyl substituents located at the para-position of the N-terminal benzoyl cap.
Isothermal titration calorimetry (ITC).
We also profiled the compound on a microarray containing 96 epigenetic reader proteins across multiple domain types.
Probe Selectivity in Vitro:
UNC3866 is selective over a broad range of chromatin-associated proteins (profiled versus 100+ Kme readers, 52 bromodomains, 33 lysine methyltransferases, and 7 demethylase enzymes). Additionally, UNC3866 was profiled against 49 GPCRs, 5 ion channels and 3 transporter proteins. In the Nature Chemical Biology publication, see Figures 2-3, Supplementary Figures 3-8, and Supplementary Tables 2-5.
In cell validation
Potency in cells:
IC50
7.6 uM
Potency assay (cells):
Consistent with inhibition of PRC1 chromodomains (Bernard, D. et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a//Arf locus. Oncogene 24, 5543-51 (2005)), UNC3866 inhibits PC3-cell proliferation in a dose-dependent manner and induces senescence after exposure for 6 days while a negative control, UNC4219, has no affect.
Target engagement assay (cells):
Whole-cell treatment of PC3 cells with UNC3866 inhibits UNC4195 (biotinylated-UNC3866)-chemiprecipitation of CBX7 from cell lysates in a dose-dependent fashion. UNC4195 chemiprecipitates endogenous CBX4/7 and other PRC1 components from cell lysates, suggesting that UNC3866 engages 'canonical' PRC1 without disrupting the complex's composition.
Potency in cells, off target:
Potency assay, off target (cells):
Assays to assess the cellular consequences of engaging the other non-PRC1 chromodomain targets (CDYs) of UNC3866 have not been performed since these are relatively uncharacterized targets.
Toxicity
Cytoxicity assay:
Yes
Notes on cytotoxicity:
Treatment with UNC3866 up to 100 uM did not induce toxic effects as assessed by CellTiter-Glo in PC3 and HEK293T cells.